Report : Middle East & Africa Tissue Engineering Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Material Type (Synthetic Material, Biologically Derived Materials, and Others) and Application (Orthopedic, Musculoskeletal & Spine, Neurology, Cardiology & Vascular, Skin & Integumentary, Urology, GI & Gynecology, Cancer, and Others)
At 9.9% CAGR, the Middle East & Africa Tissue Engineering Market is speculated to be worth US$ 954.80 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Middle East & Africa tissue engineering market was valued at US$ 493.55 million in 2022 and is expected to reach US$ 954.80 million by 2028, registering an annual growth rate of 9.9% from 2022 to 2028. Heighten advancements in regenerative medicine and rise in the healthcare market across the region.
Tissue engineering and regenerative medicine have been proposed and developed for more than 30 years. Although several successful attempts at tissue regeneration have been made, tissue engineering and regenerative medicine (TERM) is still in its infancy. Many fundamental questions remain to be answered, including the selection of cell sources, the development of tissue-specific materials, specialized bioreactors, and the construction of complex organs. After all, most therapies or treatments aim to enhance tissue regeneration, and stem cell engineering has opened a new avenue in regenerative medicine. Tissue engineering can be applied to construct various tissues such as blood vessels, nerve tissue, skin, and bones. Several techniques should be developed for stem cell engineering involving new materials, new structures, and novel surface modifications of biomaterials; a deeper understanding of the interactions between cells and biomaterials is needed. Advances in tissue engineering research and its methodology led to the formation of scaffolds for bioprinters and then to the decellularized organs. More research into processes is overcoming the shortcomings of previous methods. Improving knowledge in the biology of regeneration, development in microelectronics, and 3D printing technology helps overcome the hurdles. Rapid advancements in the development of regenerative medicines to provide more effective solutions for chronic conditions are driving the growth of the market. Cell therapy is one of the fastest-growing segments of the regenerative medicines domain. Novartis’s Kymriah was the first cell therapy solution offered for the treatment of B-cell acute leukemia, which opened opportunities for this emerging treatment therapy. Moreover, RepliCel, a regenerative medicine provider, has a wide range of regenerative medicine products in pipeline, with three products—RCH-01, RCS-01, and RCT-01—in the development phase. Further, Sernova is engaged in the development of regenerative medicine technologies and has a huge pipeline of the products for conditions such as Diabetes, Hemophilia A, and hyperthyroidism. Therefore, owing to the above-mentioned advancements the market for tissue engineering is expected to grow in the future.
On the contrary, exorbitant cost of treatment options involving tissue engineering.
Based on material type, the Middle East & Africa tissue engineering market is segment into biologically derived materials, synthetic materials, and others. The biologically derived materials segment held 52.6% market share in 2022, amassing US$ 259.42 million. It is projected to garner US$ 504.69 million by 2028 to expand at 10.0% CAGR during 2022–2028.
Based on application, the Middle East & Africa tissue engineering market is segmented into orthopedic, musculoskeletal, & spine, skin & integumentary, cardiology and vascular, neurology, cancer, gi, gynecology, urology, and others. The orthopedic, musculoskeletal, & spine segment held 34.2% market share in 2022, amassing US$ 169.38 million. It is projected to garner US$ 329.29 million by 2028 to expand at 10.0% CAGR during 2022–2028.
Based on country, the Middle East & Africa tissue engineering market has been segmented into the UAE, Saudi Arabia , South Africa, and Rest of MEA. Our regional analysis states that the UAE captured 43.1% market share in 2022. It was assessed at US$ 212.54 million in 2022 and is likely to hit US$ 431.12 million by 2028, exhibiting a CAGR of 10.6% during the forecast period.
Key players dominating the Middle East & Africa tissue engineering market are Zimmer Biomet; B. Braun Melsungen AG; Stryker Corporation; AbbVie, Inc.; Integra LifeSciences Holdings Corporation; Medtronic; Baxter International Inc.; Johnson and Johnson Services, Inc.; 3M; and Cook Biotech Inc. among others.
- In Feb 2017 Allergan acquired LifeCell Corporation, a regenerative medicine company, to strengthen its medical aesthetic, breast implants and tissue expander product portfolio.
- In November 2021, Stryker announced that it had completed the previously announced acquisition of Wright Medical Group N.V., a global medical device company focused on extremities and biologics.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org